These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21166708)

  • 21. Fluorescence in situ hybridization (FISH) results in HER2 score 1+ and 2+ breast cancers.
    Tamura G; Suzuki Y
    Pathol Int; 2016 Feb; 66(2):118-9. PubMed ID: 26314387
    [No Abstract]   [Full Text] [Related]  

  • 22. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL; Jamehdor MR; Arber JM
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 Intermediate Breast Cancers.
    Jensen KC; Nielsen TO; Gilks CB; West RB
    Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
    [No Abstract]   [Full Text] [Related]  

  • 24. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 26. Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test?
    Arena V; Pennacchia I; Carbone A; Capelli A
    J Clin Oncol; 2009 Jul; 27(19):e8; author reply e9-10. PubMed ID: 19470909
    [No Abstract]   [Full Text] [Related]  

  • 27. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
    Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
    J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases.
    Theodosiou Z; Kasampalidis IN; Karayannopoulou G; Kostopoulos I; Bobos M; Bevilacqua G; Aretini P; Starita A; Lyroudia K; Pitas I
    Breast; 2008 Feb; 17(1):80-4. PubMed ID: 17889539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue microarray technology in the routine assessment of HER2 status in invasive breast cancer.
    Cryan J; O'Grady A; Allen D; Kay E
    Histopathology; 2009 Jun; 54(7):901. PubMed ID: 19635107
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct detection of herceptin/trastuzumab binding on breast tissue sections.
    Glazyrin A; Shen X; Blanc V; Eliason JF
    J Histochem Cytochem; 2007 Jan; 55(1):25-33. PubMed ID: 16957165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of HER2 testing in the management of breast cancer.
    Ravdin P
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
    Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
    Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer.
    Rastogi P; Davidson NE
    Onkologie; 2010; 33(8-9):420-1. PubMed ID: 20838056
    [No Abstract]   [Full Text] [Related]  

  • 37. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
    Jiang ZF; Shao ZM; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
    [No Abstract]   [Full Text] [Related]  

  • 38. [HER-2/neu-testing in breast cancer: is the immunocytochemistry competent?].
    Matsionis AÉ; Pavlenko IA; Petrov AV; Povilaĭtite PE
    Arkh Patol; 2012; 74(2):42-5. PubMed ID: 22880415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
    Lebeau A; Turzynski A; Braun S; Behrhof W; Fleige B; Schmitt WD; Grob TJ; Burkhardt L; Hölzel D; Jackisch C; Thomssen C; Müller V; Untch M
    J Clin Oncol; 2010 Jul; 28(20):3264-70. PubMed ID: 20498397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.